MacroGenics, Inc.

MGNX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.5%

Institutions77.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$149.50M	$149.96M	$58.75M	$151.94M	$77.45M	$104.88M	$64.19M	$60.12M	$157.74M	$91.88M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$0	$847000	$619000	$3.35M	$2.65M	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$72.84M	-$110.58M	-$168.24M	-$121.42M	-$202.79M	-$131.06M	-$177.19M	-$171.21M	-$22.14M	-$60.04M
Operating income as a percentage of revenue.	-48.7%	-73.7%	-286.4%	-79.9%	-261.9%	-125.0%	-276.0%	-284.8%	-14.0%	-65.3%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$74.62M	-$66.97M	-$9.06M	-$119.76M	-$202.12M	-$129.74M	-$151.81M	-$171.45M	-$19.63M	-$58.53M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.00	$-1.00	$0.00	$-1.00	–	–	–	–	–	–
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	$-1.00	$0.00	$-1.00	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$57.22M	$182.84M	$100.96M	$108.88M	$123.47M	$181.13M	$126.47M	$220.13M	$211.73M	$84.10M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$256.85M	$261.65M	$298.42M	$280.47M	$335.25M	$378.74M	$312.50M	$332.13M	$373.88M	$311.26M
Everything the company owes — debt, unpaid bills, and other obligations.	$201.25M	$145.60M	$145.81M	$138.46M	$95.63M	$82.86M	$81.87M	$89.25M	$74.64M	$42.51M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$55.59M	$116.06M	$152.61M	$142.01M	$239.62M	$295.88M	$230.63M	$242.88M	$299.24M	$268.75M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$81.04M	-$68.37M	-$78.20M	-$86.96M	-$143.83M	-$111.90M	-$134.27M	-$153.23M	$14.40M	-$43.68M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.91M	$3.71M	$1.76M	$3.62M	$6.20M	$5.91M	$4.29M	$24.95M	$29.40M	$11.38M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$82.95M	-$72.08M	-$79.97M	-$90.58M	-$150.03M	-$117.80M	-$138.56M	-$178.19M	-$15.00M	-$55.06M

	You	Peer avg
Revenue Growth	+378.0%	+149.9%
ROE	-225.8%	-45.8%

MacroGenics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison